CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 1, 2006, Pages 35-39

  Kim, Jong Gwang ^a   Sohn, Sang Kyun ^a   Chae, Yee Soo ^a   Kim, Dong Hwan ^a   Baek, Jin Ho ^a   Lee, Kyu Bo ^a   Lee, Je Jung ^b   Chung, Ik Joo ^b   Kim, Hyeoung Joon ^b   Yang, Deok Hwan ^b   Lee, Won Sik ^c   Joo, Young Don ^c   Sohn, Chang Hak ^c  

^a Kyungpook National University Hospital   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Inje University   (South Korea)

Author keywords

CHOP; Etoposide; Gemcitabine; Peripheral T cell lymphoma

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; STOMATITIS; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; PREDNISONE; SURVIVAL RATE; VINCRISTINE;

EID: 33646010917     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0136-y     Document Type: Article

References (18)

1. Gordon LI, Harrington D, Anderson J, Colgan J, Glick J, Neiman R, Mann R, Resnick GD, Barcos M, Gottlieb A (1992) Comparison of a second generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 327:1342-1349
2. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006
3. Lee CH, Im YH, Ryoo BY, Nam SM, Kim MS, Lee YS, Oh KK, Shim YS, Yoo SY, Lee JO, Kang TW, Kang YK (1998) Primary CHOP chemotherapy followed by involved field radiation therapy in clinical stage I or II aggressive non-Hodgkin's lymphomas. Cancer Res Treat 30:809-817
4. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink H, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International lymphoma study group. Blood 84:1361-1392
5. Melnyk A, Rodrguez A, Pugh WC, Cabannillas F (1997). Evaluation of the revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 89:4514-4520
6. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833
7. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126
8. Koppler H, Pfluger KH, Eschenbach I, Pfab R, Lennert K, Wellens W, Schmidt M, Gassel WD, Kolb T, Hassler R (1989) CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphoma: a phase II multicenter study. Br J cancer 60:79-82
9. Karakas T, Bergmann L, Stutte HJ, Jager E, Knuth A, Weidmann E, Mitrou PS, Hoelzer D (1996) Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. Leuk lymphoma 24:121-129
10. Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R (2004) Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin's lymphoma. Cancer 101:1835-1842
11. Sallah S, Wan JY, Nguyen NP (2001) Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 113:185-187
12. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 17:1244-1253
13. Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, Cazals-Hatem D, Bosly A, Xerri L, Tilly H, Berger F, Bouhabdallah R, Diebold J (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood 92:76-82
14. Kim K, Kim WS, Jung CW, Im YH, Kang WK, Lee MH, Park CH, Ko YH, Ree HJ, Park K (2002) Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Eur J Cancer 38:75-81
15. Pfreudnschuh M, Trumper L, Kloess M, Schmits r, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rube C, Loeffler M (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633
16. Zinzani PL, Magagnoli M, Bendandi M, Orcioni GF, Gherlinzoni f, Albertini P (1998) Therapy with gemcitabine in pre-treated peripheral T-cell lymphoma patients. Ann Oncol 9:1351-1353
17. Plunkett W, Huang P, Searcy CE, Gandhi V (1996) Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23:3-15
18. Heinemann V, Hertel LW, Grindey GB, Plunkett W (1988) Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 48:4024-4031